Creutzfeldt-Jakob disease (CJD) is a rare, degenerative brain disorder that belongs to a group of conditions known as prion diseases. Specializing in infectious diseases such as CJD, our company leads the way with a distinctive range of all-inclusive services, encompassing vaccine and therapeutic development curated specifically for researchers and scientists in this specialized domain.
Overview of Creutzfeldt-Jakob Disease (CJD)
CJD manifests with rapidly progressive dementia, coordination impairments, and a plethora of other neurological symptoms. Sporadic CJD (sCJD) is the most prevalent human prion disease, with an incidence rate ranging from 1 to 2 cases per million in the population each year. Extensive human genetics research has spotlighted the STX6 and GAL3ST1 genes as notable genetic modifiers for sCJD risk apart from the PRNP gene. Such revelations underscore the multifaceted nature of CJD and the complexities inherent to its genetic underpinnings.
Fig.1 Variants of CJD and symptoms. (Rasheed, U., et al., 2024)
Pathogenesis of Creutzfeldt-Jakob Disease (CJD)
In CJD, a key feature is the abnormal folding of the prion protein, which prompts normal prion proteins to fold incorrectly. This series of misfolding events set off a harmful chain reaction, resulting in the buildup of prions, the spongy degeneration of neural tissues, the death of neurons, and the activation of astrocytes. These irregular proteins interfere with regular brain function, leading to the distinctive symptoms of CJD.
Fig.2 Trafficking of PrPSc and PrPC through endocytic and secretory pathways and relationship with SNARE protein STX6. (Jones, E., and Mead, S., 2020)
Vaccine Development for Creutzfeldt-Jakob Disease (CJD)
The development of an effective vaccine for CJD has been a significant challenge, but researchers have made some promising progress in recent years:
The vaccine uses an attenuated strain of the CJD agent to induce an immune response against prion-like proteins.
This approach involves injecting a small piece of DNA that encodes for a specific protein and triggers an immune response.
To use the prion protein peptides plus oligodeoxynucleotide-CpG to stimulate an immune response in animals.
Therapeutics Development for Creutzfeldt-Jakob Disease (CJD)
|
Types |
Names |
Mechanism of Action |
Targets |
Research Phase |
| Aminopyridine compounds |
Flupirtine |
A pyridine derivative with analgesic and anti-apoptotic properties |
Potassium channel |
Clinical trials |
| Anticoagulant |
Pentosan polysulphate |
Reduce PrPSc formation |
/ |
Clinical trials |
| Antiprotozoal drug |
Quinacrine |
Target the conversion of PrPC into PrPSc |
Aldehyde oxidase |
Clinical trials |
| Antibiotic |
Doxycycline |
Binding PrPSc conformers, hindering their assembly into amyloid fibrils |
30S subunit |
Phase II trials |
| Anti-PrPC antibody |
PRN100 |
Prion protein inhibitors |
PRNP |
Clinical trials |
Our Services
Our services cater to the diverse needs of researchers by offering cutting-edge laboratory facilities, innovative infectious disease models, and comprehensive platforms for vaccine and therapeutic development. Through a commitment to unparalleled support, advanced research materials, and the guidance of seasoned professionals, we foster an environment conducive to groundbreaking discoveries in CJD research.
Featured Services of Creutzfeldt-Jakob Disease (CJD)
- CJD-A21 model
- TgMHu2ME199K model
- ki-3F4-CJD model
- Tg23 model
- Tg5182 model
- Tg14210 model
- Others
Why Choose Us
Our steadfast commitment to excellence, innovation, and client contentment establishes us as a top-tier ally for researchers and scientists. Through consolidating services, we aim to promote smooth collaboration, boost research efficiency, and accelerate progress in comprehending and addressing infectious diseases like CJD.
If you are interested in our services, we invite you to reach out to us for further information and to obtain detailed quotations tailored to your research requirements.
References
- Jones, Emma, and Simon Mead. "Genetic risk factors for Creutzfeldt-Jakob disease." Neurobiology of disease 142 (2020): 104973.
- Rasheed, Urwah et al. "A systemic analysis of Creutzfeldt Jakob disease cases in Asia." Prion 18.1 (2024): 11-27.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
